Clinical trials: ICC, open to volunteers
Intrahepatic Cholangiocarcinoma (Icc)
Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors.
- Trial name
- NCT07640048
- Testing
- Adebrelimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
This study focused on exploring new comprehensive treatment strategies for patients with unresectable combined hepatocellular-cholangiocarcinoma, classifying patients with CHC subtypes based on the combination of artificial…
- Conditions
- Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
- Trial name
- NCT06849180
- Testing
- Interventional therapies combined with or without systemic drugs
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Zhongda Hospital
Intrahepatic Cholangiocarcinoma
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Underlying disease mechanisms are fundamental for correct treatment selection and patient management in highly invasive and debilitating non-transmissible diseases.
- Trial name
- PM-CARE (NCT06375915)
- Testing
- radioembolization with Y-90, Durvalumab, Cisplatin
- Where
- 4 sites in Italy
- Volunteers
- 33 people
- Sponsor
- Francesco De Cobelli
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
The purpose of this multicenter pragmatic randomized controlled trial is to determine whether AI-assisted interpretation of multiphasic liver contrast-enhanced computed tomography (CE-CT) is non-inferior to standard radiology…
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07768085
- Testing
- AI-assisted abdominal CE-CT reporting, Standard abdominal CE-CT reporting without AI assistance
- Where
- China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Intrahepatic Cholangiocarcinoma (Icc)
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic…
- Trial name
- iCOLA (NCT06862934)
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Intrahepatic Cholangiocarcinoma
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and occurs proximal to the segmental biliary ducts.
- Trial name
- GOT (NCT05557578)
- Testing
- Tislelizumab combined with GEMOX (GOT) regimen
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma (Icc), Liver Injury
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
The goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed.
- Trial name
- NCT07760038
- Testing
- Phycocyanin, Maltodextrin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intrahepatic Cholangiocarcinoma (Icc)
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
This is a multicenter, open label, randomized, two-arm clinical study to observe and evaluate the efficacy and safety of adebrelimab combined with irinotecan liposomes, 5-fluorouracil, calcium folinate ± lenvatinib as first-line…
- Trial name
- NCT06648525
- Testing
- Adebrelimab, Irinotecan liposomes, Lenvatinib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Harbin Medical University
Intrahepatic Cholangiocarcinoma (Icc), HAIC
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
At present, the first-line treatment for patients with advanced unresectable intrahepatic cholangiocarcinoma is mainly systemic treatment, but the improvement in efficacy is limited and is not enough to meet the current clinical…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), HAIC, Durvalumab
- Trial name
- HAIC-quad (NCT06859684)
- Testing
- Durvalumab, hepatic arterial infusion chemotherapy (HAIC), Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC)
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
Primary liver cancer, mainly including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), represents the third leading cause of cancer-related mortality.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer
- Trial name
- NCT07101237
- Testing
- Multi-modal ultrasonic imaging system for liver cancer
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Peking Union Medical College Hospital
ICC
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients
- Trial name
- NCT06447454
- Testing
- radiotherapy, gemcitabine + cisplatin, slulimumab
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant concurrent chemoradiotherapy with simultaneous integrated boost following hepatectomy for intrahepatic cholangiocarcinoma…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement
- Trial name
- NCT07063888
- Testing
- Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
The goal of this prospective observational study is to evaluate whether Gallium-68 Fibroblast Activation Protein Inhibitor (FAPI) PET/CT can improve detection, staging, and recurrence assessment in adult patients (≥18 years) with…
- Trial name
- FAPi-2 (NCT07337850)
- Testing
- gallium-68-Fibroblast Activation Protein Inhibitor
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
This is a prospective, open-label, single-arm phase II study designed to evaluate the efficacy and safety of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) in combination with donafenib and pucotenlimab as first-line…
- Trial name
- NCT07353827
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Donafenib, Pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Radioembolization, Hepatocellular Carcinoma (HCC)
Scout Dose of Resin Microspheres
This study looks at a liver cancer treatment called radioembolization and tests a new, possibly more accurate way to check if the treatment is safe for a patient's lungs.
- Conditions
- Radioembolization, Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Liver Metastasis
- Trial name
- LASER (NCT07476651)
- Testing
- scout dose
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital